An interventional study of 3D simulation of placement of neurovascular implantable medical device and Manual planning of endovascular procedure in Unruptured Intracranial Aneurysm, sponsored by Sim&Cure. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Sim&Cure · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.
Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 64th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:
Resolve Stroke · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
Phenox GmbH · Sites in France, Germany, Italy and 2 more countries
Hospices Civils de Lyon · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 576 is above the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 171 across the 23 interventional studies, 206 across the 43 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 66 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sim&Cure as lead sponsor.
Sim&Cure has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
4 of the studies in Intracranial Aneurysm with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04192955Phase 3University of CalgaryEvaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms | 2027-03 |
| NCT07864389Resolve StrokeMultimodal Approach Feasability Study for Untreated and Unruptured Intracranial Aneurysms | 2026-11 |
| NCT06940934Acandis GmbHPost-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE | 2026-12 |
| NCT06689410Nantes University HospitalMultimodal Biocollection Linked to the French Register of Intracranial Aneurysms | 2027-03-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Intracranial Aneurysm with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In recent years, endovascular treatment of intracranial aneurysms has seen remarkable growth, now surpassing traditional surgical approaches in terms of frequency of use. However, this transition to endovascular methods is not without its challenges. This type of procedure requires careful selection of the device to be implanted, a decision that is still based on manual two-dimensional measurements. This method is questionable, as it does not always take into account the complexity and specificities of certain aneurysms, where three-dimensional geometry can play a crucial role. As a result, these procedures carry significant risks, such as the need for additional maneuvers to remove or reposition devices, or even deploy another support device, which potentially increases the risk of perioperative complications, the duration of surgery, and the amount of radiation required for imaging. Beyond the impact on the patient, these complications also result in additional costs for the healthcare system, expenses that could likely be avoided if more precise and appropriate tools were used from the outset of the procedure. In this context, optimizing the choice of endovascular devices could have both clinical and economic impacts. Innovative technology such as Sim\&Size, which supports healthcare professionals in their therapeutic decisions and choice of the appropriate endovascular device, should therefore improve the effectiveness and efficiency of endovascular treatments.
Sim\&Size is a Software as a Medical Device (SaMD) intended to provide a 3D view of the final placement of neurovascular implantable medical devices of the following types: flow diverters, intrasaccular devices, stent devices, and coils. It uses an actual image of the patient produced by 3D rotational angiography. It offers physicians the possibility of simulating the deployment of implantable medical devices in the artery to be treated and predicts the final placement and the extent of apposition of the implant. Sim\&Size has CE marking and FDA clearance.
This study is a prospective, randomized, multicenter study whose main objective is to show that the use of Sim\&Size during the standard endovascular procedure, compared with a standard endovascular procedure without Sim\&Size, reduces both the actual costs of the hospital stay and the rate of perioperative complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Investigator will use manual two-dimensional measurements to assess which neurovascular implantable medical device to use to treat the intracranial aneurysm.
Other: Manual planning of endovascular procedure
Investigator will use Sim\&Size software, which allows for three dimensional representation of the aneurysm and for simulation of the placement of different types of devices, to support the choice of the neurovascular implantable medical device used to treat the intracranial aneurysm.
Other: 3D simulation of placement of neurovascular implantable medical device
Using the Sim\&Size software to obtain a 3D view of the final placement of neurovascular implantable medical devices of the following types: flow diverters, intrasaccular devices, stent devices, and coils, using an actual image of the patient produced by 3D rotational angiography. Used in the treatment of intracranial aneurysm.
Manual planning of endovascular procedure using 2D images for placement of implantable medical devices for treatment of intracranial aneurysm.
Impact of Sim&Size use during endovascular procedure on healthcare costs
The main objective is to compare the use of Sim\&Size during a standard endovascular procedure versus manual planning in modifying the healthcare costs of the hospital stay. This objective will be demonstrated through the use of the following criteria: -Difference in average direct hospital costs between the two groups. The two primary outcomes measures will be analyzed in a sequential hierarchical manner
Time frame: From enrollment to the end of follow-up at 6 months
Impact of Sim&Size use during endovascular procedure on perioperative complications
The main objective is to compare the use of Sim\&Size during a standard endovascular procedure versus manual planning in modifying the rate of perioperative complications. This objective will be demonstrated through the use of the following criteria: Difference in the rate of perioperative complications. The two primary outcomes measures will be analyzed in a sequential hierarchical manner
Time frame: From enrollment to the end of follow-up at 6 months
Demonstrate a change in average hospital costs by type of endovascular device used
Demonstrate a change in average healthcare costs by type of endovascular device used (flow diverter, coils or intra-saccular device)
Time frame: From enrollment to end of follow-up at 6 months
Demonstrate a change in rate of perioperative complications by type of endovascular device used
Demonstrate a change in rate of perioperative complications by type of endovascular device used
Time frame: From surgery to the end of follow-up (6 months)
Change in the rate of aneurysm(s) recurrence
Demonstrate a change in the rate of aneurysm(s) recurrence at six months. Recurrence is defined as inadequate occlusion of the aneurysm on follow-up imaging at six months.
Time frame: At 6 months post surgery
Change in operating time
Demonstrate a change in operating time during the endovascular procedure (in minutes)
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change of device deployment time
Demonstrate a change in the device deployment time during the endovascular procedure (in minutes)
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change in the number of endovascular devices used
Demonstrate a change in the number of implantable devices used during the endovascular procedure
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change in the number of wasted implantable devices
Demonstrate a change in the number of devices opened but not implanted or implanted but removed during the endovascular procedure. An opened device cannot be reused.
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change in the amount of imaging performed during the endovascular procedure
Change in the number of angiography and computed tomography imaging series performed during and immediately after deployment
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change in radiation exposure due to imaging
Demonstrate a change in radiation exposure (in mGy)
Time frame: From beginning to end of surgery (maximum of 24 hours)
Change in duration of hospital stay
Demonstrate a modification of the duration of hospital stay (in days) from entering the hospital to exiting the hospital.
Time frame: From entering the hospital to exiting the hospital (maximum of 1 month)
Change in the number of intensive care unit transfers/stays
Demonstrate a change in the number of intensive care unit transfers/stays after the surgery
Time frame: From the surgery to the end of the follow-up at 6 months
Description of decreased healthcare costs linked to the use of Sim&Size
Qualitative and quantitative analysis of hospital resources saved through the use of Sim\&Size
Time frame: From enrollment to the end of follow-up at 6 months
Cost/consequence analysis of the use of Sim&Size
Carry out a cost/consequences analysis to compare the difference in costs observed in the main criterion with the multiple clinical consequences for the patient.
Time frame: From enrollment to the end of follow-up at 6 months
Plan to share: Undecided
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 26 months is close to that.
Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.